Financiado en parte por Eli Lilly and Company, H. Lundbeck A/S
Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and Biological Studies
Chang JP, Su KP, Mondelli V, Pariante CM
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 160 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Eli Lilly and Company
- Universidad u hospital
- South London and Maudsley NHS Foundation Trust
- Gobierno
- National Institute for Health and Care Research
- Organización sin fines de lucro
- Academy of Medical Sciences
- Universidad u hospital
- King's College London
- Universidad u hospital
- China Medical University
- Empresa
- H. Lundbeck A/S
- Gobierno
- Medical Research Council
- Gobierno
- National Institute for Health Research (NIHR)
- Subvenciones
- National Institute for Health and Care Research (CL-2008-17-005); Eli Lilly and Company (MR/J002739/1); South London and Maudsley NHS Foundation Trust (MR/L014815/1); Medical Research Council (MR/L014815/1); National Institute for Health and Care Research (MR/J002739/1); National Institute for Health and Care Research (MR/L014815/1); Academy of Medical Sciences (AMS-SGCL5-Mondelli); South London and Maudsley NHS Foundation Trust (MR/J002739/1); National Institute for Health and Care Research (NF-SI-0616-10074); Medical Research Council (MR/N029488/1); Medical Research Council (MR/J002739/1); Medical Research Council (MR/J002739/1); Medical Research Council (MR/L014815/1)
Según 9 financiadores declarados.
Publicación
- Publicado
- 2017-07-25 · Neuropsychopharmacology · vol. 43 · número 3 · págs. 534–545
- Editorial
- Springer Nature
- Citado
- 248 citas · más que el 96% de estudios similares · 1.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 59 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Fatty Acid Research and Health · Attention Deficit Hyperactivity Disorder · Aquaculture Nutrition and Growth
- Palabras clave
- omega-3 polyunsaturated fatty acids, attention deficit hyperactivity disorder, children and adolescents, dietary supplementation, docosahexaenoic acid, EPA, ADHD symptoms, cognitive performance, fatty acid deficiency, buccal tissue, blood fatty acid levels
- MeSH
- humans, fatty acids, omega-3, attention deficit disorder with hyperactivity, adolescent, child, randomized controlled trials as topic
4 autores
- Jane Pei‐Chen Chang🇬🇧🇹🇼 · autor de correspondenciaKing's College London; China Medical University; China Medical University Hospital
- Kuan‐Pin Su🇬🇧🇹🇼King's College London; China Medical University; China Medical University Hospital
- Valeria Mondelli🇬🇧King's College London
- Carmine Maria Pariante🇬🇧King's College London
Resumen
El texto original del estudio, en el idioma en que se publicó.
The role of omega-3 polyunsaturated fatty acids (omega-3 or n-3 PUFAs) in the pathogenesis and treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD) is unclear. A systematic review followed by meta-analysis was conducted on: (1) randomized controlled trials (RCTs) assessing the effects of n-3 PUFAs on clinical symptoms and cognition in children and adolescent with ADHD; and (2) case-control studies assessing the levels of n-3 PUFAs in blood and buccal tissues of children and adolescents with ADHD. In seven RCTs, totalling n=534 randomized youth with ADHD, n-3 PUFAs supplementation improves ADHD clinical symptom scores (g=0.38, p<0.0001); and in three RCTs, totalling n=214 randomized youth with ADHD, n-3 PUFAs supplementation improves cognitive measures associated with attention (g=1.09, p=0.001). Moreover, children and adolescents with ADHD have lower levels of DHA (seven studies, n=412, g=-0.76, p=0.0002), EPA (seven studies, n=468, g=-0.38, p=0.0008), and total n-3 PUFAs (six studies, n=396, g=-0.58, p=0.0001). In summary, there is evidence that n-3 PUFAs supplementation monotherapy improves clinical symptoms and cognitive performances in children and adolescents with ADHD, and that these youth have a deficiency in n-3 PUFAs levels. Our findings provide further support to the rationale for using n-3 PUFAs as a treatment option for ADHD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.